Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06852768 · ClinicalTrials.gov registry record · Phase 1
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
A Phase 1 study of oGHVD, sponsored by Regenerative Ocular Immunobiologics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 5
- Study locations
NCT06852768 is a Phase 1 study of oGHVD that is actively recruiting participants, run by Regenerative Ocular Immunobiologics. The registered enrollment target is 1 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT06852768, a Phase 1 study of oGHVD, is actively recruiting participants, sponsored by Regenerative Ocular Immunobiologics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL d-MAPPS
- OTHER PI and Patient Masked
Study Locations (5)
California
- Beverly Hills Institute of Ophthalmology - Beverly Hills
- Beach Eye Medical Group - Huntington Beach
Florida
- Regenerative Ocular Immunobiologics, LLC. - Palm Harbor
Kentucky
- Glenn Eye Center - Lexington
Massachusetts
- Eyewell, LLC. - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06852768
The ClinicalTrials.gov registry entry for NCT06852768 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regenerative Ocular Immunobiologics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with oGHVD appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06852768 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06852768 about?
NCT06852768 is a clinical study titled "Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)". A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)
What is the current status of trial NCT06852768?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2025-01-10. Estimated completion is 2026-12.
What conditions does trial NCT06852768 study?
This clinical trial studies the following conditions: oGHVD.
What interventions are being tested in trial NCT06852768?
The interventions under investigation include: Placebo (BIOLOGICAL), d-MAPPS (BIOLOGICAL), PI and Patient Masked (OTHER).
Who is sponsoring clinical trial NCT06852768?
This trial is sponsored by Regenerative Ocular Immunobiologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06852768 being conducted?
This trial has 5 study locations across California, Florida, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.